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1. Introduction 
With increasing awareness of the indications of implantable cardioverter defibrillator (ICD) 
therapy, the number of patients with ICDs has been growing rapidly. Patient with an ICD 
require high-quality care and intense follow-up to ensure safe and effective device 
performance. Given the expanding use and the complexity of these devices, there has been 
an urgent need to improve the safety and cost-effectiveness of ICD follow-up and to 
alleviate the burden of the pacemaker clinics. Remote monitoring is quickly becoming the 
standard of care for surveillance of patients with ICDs and other cardiovascular implantable 
electronic devices (CIED). Transtelephonic data transmission via analog phone lines has 
recently been replaced by sophisticated Internet-based, automatic monitoring systems, 
which enable transmission of ICD performance and therapy data via a mobile monitor 
located in the patient’s home to a secure server. Within minutes, the data are available to the 
physician online via a secure Internet access 24/7.  
Each company employs somewhat different technology and degree of automation in their 
systems. For several years Biotronik was the only company with fully automatic wireless 
data transmission, but recently also the other manufactures have developed GSM-based 
wireless systems. Currently remote monitoring systems are widely used for the surveillance 
of ICD patients in the USA and Europe and their use in the other parts of the world is 
increasing rapidly. We were the first to start using the Medtronic CareLink system in 
Europe in 2004. It has been estimated that at the moment more than 1 000 000 patients with 
CIEDs around the world are using remote monitoring systems. The technology is evolving 
toward fully automated wireless remote monitoring systems which allow instantaneous 
event transmission without any patient involvement and have the ability of rapidly bring to 
the physician attention all significant data. Recent trials have demonstrated that remote 
monitoring reduces clinic burden, and permits early detection of patient and device 
problems, enabling clinically appropriate intervention and an opportunity to enhance 
patient safety. 
In this article, we describe the currently available remote monitoring systems (Table 1), 
review the available evidence in the literature regarding remote ICD follow-up and discuss 
some unresolved issues. In addition, we provide several examples that clarify the benefits of 
the remote ICD monitoring. 
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Manufacturer Name of the system ICD CRT PM ILR 
Biotronik Home Monitoring + + + - 
Boston Scientific LATITUDE + +* - - 
Medtronic CareLink + + + + 
St Jude Medical Merlin.net + + + + 
Table 1. Remote monitoring systems of the major CIED manufactures. ICD = implantable 
cardioverter defibrillator, CRT = cardiac resynchronization therapy with (CRT-D) or 
without defibrillator functions (CRT-D), PM = conventional pacemaker, ILR = implantable 
loop recorder. *The LATITUDE system is currently compatible only with CRT-D devices. 
2. Overview of currently available remote monitoring systems 
Since Biotronik pioneered the technology with FDA approval of their first system in 2001, 
remote monitoring systems have now been introduced by each of the major CIED 
manufacturers. Presently remote monitoring is primarily used for the surveillance of ICD 
systems, but the technology is also feasible for the follow-up of other CIEDs including 
pacemakers (PM), cardiac resynchronization devices (CRT), implantable loop recorders 
(ILR) and implantable cardiovascular monitors (ICM). 
A remote monitoring system consists of an implanted device, a mobile patient monitor, a 
central database in a secure server, and a password-protected website, where clinicians can 
view and analyze the data saved in the memory of the patient's device (Figure 1). Systems 
differ regarding data transfer from the device to the patient monitor. In the early models 
data transfer required patient’s active involvement as he/she had to interrogate the device 
manually with a specific wand. In the more recent systems data transmission is performed 
wirelessly from the implanted device to a patient monitor, but each company employs 
somewhat different technology and degree of automation in their systems. 
 
 
Fig. 1. Components of remote monitoring system. Systems differ regarding data transfer, 
which may require patient’s active involvement or is performed wirelessly from the 
implanted device to a patient monitor. Data from the patient monitor is sent to a central 
database using either an analogue phone landline or via GSM network. The data are 
accessible to the clinical staff on a secure Internet site.  
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Patient initiated remote transmission requires that the patient manually interrogates and 
initiates the data transmission using a telemetry wand incorporated in the home transmitter. 
This encounter may be a scheduled follow-up interrogation or an unscheduled interrogation 
activated by a patient symptom (e.g. ICD shock) or detection of a device alert (audible tone 
or vibration). Wireless technology allows for automatic data transmission without any 
patient interaction. Automatic wireless interrogation requires that the implanted device is 
equipped with an integrated antenna for communication with the transmitter located close 
to the patient (Figure 2). Data transmission is initiated either at pre-scheduled time intervals 
or triggered immediately by programmed device alerts (e.g. abnormal lead impedance, 
delivery of ICD therapies, or changes in hemodynamic status). 
 
 
Fig. 2. An advanced ICD with an internal antenna for wireless data transmission to the 
patient monitor. 
Data from the patient monitor is sent to a central database using either an analogue phone 
landline or via a GSM network. Within minutes from transmission, the processed data are 
accessible to the follow-up physician on a secure Internet webpage when and where he/she 
chooses. Available information includes all data within the device memory, which is 
comparable to the information provided during an in-clinic device follow-up visit. When a 
therapy-relevant event or device status change is detected, remote monitoring system also 
generates an event alert via email, SMS, or fax to the physician while simultaneously 
displaying the severity of alert on the internet website. 
Devices with CRT-delivery have the capability to track the percentage of biventricular 
stimulation and several physiologically diagnostic parameters such as heart rate, heart rate 
variability, and patient activity. Some devices include also fluid status monitoring by 
assessing intrathoracic impedance. Fluid accumulation within the lungs leads to a decrease 
in impedance and provides an early indication of congestion. Remote monitoring system 
automatically generates wireless alert notification when the device detects a loss of CRT 
delivery or a change in hemodynamic status indicating risk for worsening heart failure. 
3. Safety of remote ICD monitoring 
Remote monitoring is easy to use and it provides a feasible alternative for long-term 
surveillance of patients with ICD. It allows the physician to view and analyze transmitted 
device data from any computer in a format similar to the information gathered during a 
typical in-clinic visit (Figure 3). In addition to the device parameters (e.g. battery voltage and 
longevity, lead impedance and trends, automatic capture thresholds) and the summary of 
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stored ventricular and supraventricular arrhythmia episodes, the physician can also review 
the intracardiac electrograms of the arrhythmic events (Figure 4) and a real-time 
electrogram with the presenting rhythm. The information is automatically saved on the 
server for future comparison and analysis. 
 
 
Fig. 3. Example of stored device data in the Medronic CareLink network. The patient had 
had 4 fast VT episodes. 
Studies have shown a >90% successful transmission rate of automatically generated data 
collected by the device within several minutes and no direct safety issues with remote 
monitoring have been identified (Varma et al., 2005). It has been estimated that remote 
www.intechopen.com
 Remote Monitoring of Implantable Cardioverter-Defibrillator Therapy 
 
239 
monitoring of ICD patients can potentially diagnose >99,5% of arrhythmia- and device-
related problems (Heidbüchel et al., 2008). In our study physicians were satisfied with the 
performance of the system and found the data comparable to traditional device 
interrogation in the majority of the cases. In 2 of 137 cases, the physicians felt that an in-
office visit would have provided more detailed information of the device function, because 
it was not possible to measure the pacing threshold remotely. 
Remote monitoring systems do not allow remote programming of devices or manual 
determination of pacing thresholds. Although technically feasible, protecting patient safety 
is the primary concern not to enable remote programming yet. Meanwhile, most new 
devices have automatic features to measure pacing and sensing thresholds. The lack of 
possibility for remote programming appears also as an issue of minor relevance during the 
routine ICD follow-up. In a retrospectively analyzed data of 1739 ICD follow-up visits by 
Heidbüchel et al (2008), changes in device programming were made only in 4% of all 
scheduled follow-up visits. Likewise, problems with pacing threshold were detected only in 
0,4% of the evaluations and typically in the early postoperative period. Due to the clustering 
of system-related complications in the early postoperative period, in-clinic visits are 
recommended for the post-implant and after 4-12 weeks follow-ups for patients with remote 
monitoring (Wilkoff et al., 2008). 
4. Efficiency of remote ICD follow-up 
According to the current HRS/EHRA expert consensus on the monitoring of CIEDs, 
patients with an ICD should be followed up in person after implantation and subsequently 
every 3-6 months (Wilkoff et al., 2008). More frequent monitoring may be required when the 
device approaches its elective replacement indicator. During the maintenance phase of 
follow-up and when the patient's medical condition is stable and no anticipated device 
programming is required, follow-ups can be accomplished remotely. It is also recommended 
that any patient with an ICD should be assessed in-clinic once a year. 
Remote monitoring technology reduces the need for hospital visits and may facilitate, 
when needed, visits triggered by clinical event. It has been estimated that remote follow-
up could be used to replace majority of scheduled in-clinic visits, as in only 10% of routine 
follow-ups does device interrogation lead to changes in medical treatment or device 
programming (Heidbüchel et al., 2008). Unscheduled clinic visits initiated by the patient 
due to perceived ICD shocks, other arrhythmic events or system related complications are 
actionable more often, in 40-90% of the cases. Thus, of the majority of the patient-initiated 
unscheduled clinic visits could be managed by remote monitoring with no need to visit 
the device clinic. 
Our results showed that at least two out of three in-clinic visits can replaced by scheduled 
remote monitoring data transmission without compromising the safety of the patients 
(Raatikainen et al. 2008). The data from the TRUST trial demonstrated in the first 
prospective, randomized multicenter study that remote home monitoring with wireless 
automatic daily surveillance can safely and effectively replace conventional in-hospital ICD 
follow-up visits (Varma et al., 2010). The results showed that remote monitoring with only 
one scheduled annual in-clinic visit reduced the overall number of clinic visits by 45% 
without any negatively impact on quality of care or safety of the patients. Remote 
monitoring provided sufficient assessment in the majority of 3-monthly follow-ups, in 85,8% 
of the cases. In addition, the TRUST trial also demonstrated that automatic daily 
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surveillance provided early detection and notification of both symptomatic and 
asymptomatic arrhythmic events and device system anomalies allowing for earlier 
physician intervention than conventional in-hospital follow-ups. Detection was advanced by 
more than 30 days compared with conventional care.  
According to our data the time needed by the patients for remote data transmission (6.9+3.7 
min) was significantly shorter than the duration of an in-office visit, which took over six 
hours (391+282 min) when the travel time was included in the analysis. The average one-
way distance and travel time to the hospital were 130+95 km (range 3–350) and 182+148 min 
(range 10–670 min), respectively. Most patients (90%) found the system convenient to use 
and classified the time needed for the remote data transmission for all follow-ups as very 
short (21%) or short (69%). 
5. Workflow of the device clinic 
It is obvious that remote monitoring reduces significantly the device clinic workload for 
routine cases by decreasing the number of non-actionable in-clinic visits. In addition, remote 
follow-up requires less physician and technician or nurse time than in-clinic follow-up. In an 
Italian study (Masella et al., 2008), remote follow-up with the CareLink system required on 
average 5 minutes per transmission compared with 15 minutes for in-clinic follow-up. In 
keeping with this, our data indicated that prescheduled data transmission significantly 
alleviated the time burden of the device clinic staff. In our study, two of four in-office visits 
were substituted by remote monitoring. As a result the physicians had at least 45 min and 
the nurses 90 min more time for other activities per patient during the 9-months study 
period, respectively (Raatikainen et al. 2008). New wireless remote monitoring systems 
allow automatic data transmission on a daily basis and instantaneous event transmission 
without any patient involvement. This permits physicians and clinic staff to focus on 
patients who urgently require a consultation for diagnostics or treatment.  
Recently, remote monitoring with automatic data transmission has been shown to improve 
early detection of device malfunction and asymptomatic arrhythmias such as atrial 
fibrillation. On the other hand, it has been postulated that automatic transmission of all 
device- or therapy-related events via a fully automated wireless remote monitoring system 
may pose a challenge to workflow in ICD clinics. Transmitted data should be assessed in a 
regular timely fashion and responded to if events are observed. The remote monitoring 
system quickly and easily identifies patients who need immediate attention by 
automatically reviewing, filtering and communicating clinically relevant patient and device 
status data. Despite daily remote monitoring, the event alert notifications are triggered 
infrequently and most can be managed remotely. In the TRUST trial (Varma et al, 2010), 
about 90% of the alert notifications were managed remotely. Thus, replacement of routine 
in-clinic visits with remote monitoring only slightly raised the number of unscheduled in-
clinic visits (0,7 vs. 0,5 per year). The commonest trigger for the transmission of event alert 
was the detection of atrial tachycardia or atrial fibrillation. In our study there were 18 
unscheduled patient- or physician-initiated data transmissions during the study period. In 
accordance with the results of Varma et al. (2010), all of these were solved remotely and the 
patient did not need to come to the hospital for reassurance. An example of a symptom-
initiated data transmission which was solved remotely is shown in Figure 2. Other events 
which have been commonly diagnosed and treated on the basis of symptom-initiated data 
transmissions include atrial fibrillation and “phantom” shocks. 
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In a study by Nielsen et al (2008), automatic wireless remote monitoring generated event 
notifications for 41% of ICD patients over a 10-month period. Most events caused by 
medical events such as arrhythmias and only about 3% of patients had technical events. 
Probability of any alert event after 1,5 years was 0.50. Less than one (mean of 0,86) event 
notifications was received per 100 patients per day. Ricci et al (2008) reported a mean time 
for remote data analysis of 59 min/week for the nurse and 12 min/week for the physician 
per 117 patient transmissions, when only 6% of events were forwarded to the physician for 
further evaluation. The time effort on the management of patients with remote monitoring is 
likely to reduce even more with the integrated automatic filtering functions. 
 
 
Fig. 4. Patient-initiated unscheduled data transmission. The patient had occasional 
palpitation about once a month. The remote data transmission revealed a fast VT episode 
that was appropriately treated by the device with single burst pace therapy and there were 
no need for an in-office visit. Shown are the interval (V–V) plot (A) and intracardiac ECG (B) 
obtained during the symptoms. In the more advanced systems the episode data would have 
been transmitted automatically. 
6. Effect on patient care and safety 
The information transmitted via the remote monitoring system is comparable to what is 
typically obtained during an in-clinic device follow-up. Hence, it provides the clinician with 
a comprehensive view of how the patient's heart and device are working. In addition, 
automatic remote monitoring early detects silent clinically relevant events and device 
system problems, allowing more timely treatment decisions and intervention. Earlier 
treatment intervention can ultimately result in improved clinical outcomes and reduce 
healthcare costs.  
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Lead failure is a long-term complication of ICD therapy. The annual rate of ICD leads 
requiring intervention increases with time and reaches 20% in 10-year-old leads (Kleemann 
et al., 2007). Inappropriate shocks due to noise oversensing are revealed as the most 
common presentation of lead failure. Studies have shown that early detection of lead failure 
by remote monitoring may reduce the risk of inappropriate ICD shocks (Hauck et al., 2009, 
Spencker et al., 2009). Spencker et al (2009) reported that fewer patients undergoing remote 
monitoring experienced ICD shocks for sensing failure prior to lead revision than those with 
standard in-clinic follow up. Inappropriate shocks occurred in 27,5% of the patients 
followed remotely compared with 46,5% of those followed up in-clinic. In 91% of all 
incidents, remote monitoring system transmitted an early alert message that enabled the 
correct diagnosis of lead failure. By accurately detecting lead failures, remote monitoring 
has also proven to be useful in the follow-up of ICD leads under advisory (Swerdlow et al., 
2008, Theuns et al., 2009, Guédon-Moreau et al., 2010). An example of a lead problem which 
could actually have been detected by remote monitoring already a day before the 
inappropriate shock Figure 3. 
 
 
Fig. 3. Automatic data transmission showing high number of short V-V intervals suggesting 
double counting of R waves, lead fracture or loose set of screw. The impedance of the lead 
increased markedly on 09/10/08, i.e., day before the patient had an inappropriate shock due 
to the lead fracture. 
Recently the CONNECT trial for the first time showed that remote follow-up actually 
creates reliable outcome measures which improves care (Crossley et al., 2011). The study 
measured the time from an adverse event to a clinician’s decision on how to handle it in 
patients with an ICD with or without CRT capabilities randomized to wireless remote 
monitoring with automatic clinician alerts versus standard in-clinic care. The results showed 
that remote monitoring significantly reduced the time from a clinically-actionable event to a 
clinical decision. The median time from a patient’s clinical event (arrhythmias, 
cardiovascular disease progression, and device issues) to the physician’s clinical decision 
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was 22 days for those monitored in-clinic, versus 4.6 days for patients in the remote 
monitoring group. The data also showed that remote monitoring reduced average length of 
cardiovascular hospital stay by 18% (0,7 days). Due to the shorter length of stay, 
cardiovascular hospitalization costs were reduced by an estimated $1,793 per 
hospitalization. Furthermore, the data showed that replacement of routine in-clinic visits 
with remote monitoring did not significantly increase other healthcare utilization, such as 
emergency room visits, cardiovascular hospitalizations, and unscheduled clinic visits. 
 
 
Fig. 4. Inappropriate shock due to lead fracture. Shown are the V-V interval plot and 
intracardiac ECG. It can be seen that the lead fracture resulted in oversensing of noise in the 
VT and fast VT zone which caused an inappropriate shock. 
Inappropriate shocks are due to lead fracture (Figure 4.), misdiagnosis of sinus tachycardia 
(Figure 5.) or rapidly conducted AF/AT episodes are also a major concern among ICD 
recipients. Inappropriate shocks are painful for the patients and also potentially life-
threatening. In a recent analysis (van Rees et al., 2011), the first inappropriate ICD shock 
increased the risk of death by 60%. Mortality risk increased with every subsequent shock. 
Detection of problems such as sinus tachycardia and T-wave oversensing through remote 
monitoring followed by prompt device reprogramming may prevent new episodes that 
could lead to inappropriate therapies (Sacher et al., 2009). 
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Fig. 5. Event notification via CareLink remote monitoring system. The V-V interval plot 
and the IEGM show inappropriate ATP-therapy delivery due sinus tachycardia. The 
patient was invited to device clinic for reprogramming of the device and adjustment of 
medication. 
Several prospective randomized studies are presently underway on the clinical effectiveness 
of event-triggered active heart failure and AF management though remote monitoring in 
reducing cardiovascular related hospitalizations and mortality in patients with an ICD or a 
CRT-D device. In the ALTITUDE study (Saxon et al., 2010), analysis of a large 
manufacturer’s database of ICD patients undergoing remote monitoring with LATITUDE 
system showed higher survival rates for patients followed remotely than those followed in-
clinic only. Survival outcomes in ALTITUDE appeared also better than those observed 
previously in clinical trials, suggesting that closer management though remote monitoring 
allows to intervene more effectively with impact on survival. 
An additional benefit is that remote monitoring provides convenient means to address the 
situation that the ICD or its leads can become subject to the an official safety advisory 
(“recall”). With remote monitoring, patients with advisory devices can be followed more 
closely, their issues addressed more promptly, and clinicians and device manufacturers get 
exquisitely detailed data on how the device is performing. 
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7. Patient preference 
Several studies have shown a high degree of patient satisfaction with the convenience and 
ease of use of remote monitoring systems (Marzegalli et al., 2008, Masella et al., 2008, 
Raatikainen et al., 2008). From a patient’s perspective, the biggest value of remote 
monitoring is convenience with fewer in-clinic visits and less time traveling to and from 
their clinics. Remote monitoring also leads to greater patient reassurance and improved 
patient follow-up adherence (Varma et al., 2010). Most patients prefer remote monitoring 
over in-clinic visits (Marzegalli et al., 2008, Masella et al., 2008). In TRUST trial, 98% of 
patients elected to retain remote monitoring as a follow-up mode on trial conclusion (Varma 
et al., 2010).  
The current HRS/EHRA expert consensus states that remote monitoring of ICD devices is 
indicated when the patient’s medical condition is stable and no anticipated device 
programming is needed (Wilkoff et al., 2008). The technology is not, however, intended to 
replace direct patient contacts completely. In-clinic visits are recommended for the post-
implant follow-up, after 2-12 weeks  and at least once a year. If the patient’s cardiovascular 
status is unstable, in-clinic visit may be required to address the management of the 
underlying medical problem. The continuation of patient’s clinical follow-up for the heart 
failure management should be ensured regardless of the place of care. 
8. Cost effectiveness 
As a result of expanding indication for use and complexity of the devices, the costs 
associated with ICD follow-up have risen sharply over the past several years. Remote 
monitoring may result in reduced overall costs to the healthcare system, although the cost-
effectiveness will highly depend on differences in national healthcare systems. Potential cost 
savings of remote monitoring would include a reduced number of scheduled in-clinic visits 
and fewer hospitalizations due to early identification of problems followed by prompt 
intervention. It can be calculated that if remote monitoring were to be applied to all the 
patients with new ICDs, the annual saving for the healthcare system in Western Europe, 
would be 16–23 million Euros. In addition, remote monitoring gives physicians extra time to 
counsel patients with critical conditions, ensuring medical efficiency, and better overall 
patient management, which is expected to reduce the cost of the treatment even further. 
The major indirect cost driver in the ICD follow-up is travelling to the hospital. Therefore, 
the greatest cost benefit is expected among patients who live far away from the device clinic 
and are still actively working (not retired). Several studies have evaluated the cost savings 
attributable to remote monitoring of ICD devices (Fauchier et al., 2005, Elsner et al., 2006, 
Raatikainen et al., 2008). The greatest benefit is seen among patients with long traveling 
distances to the device clinic. In a French study (Fauchier et al., 2005), remote monitoring 
appeared cost-effective for patients after a mean follow up of 33.5 months by saving on 
transportation costs. In our study (Raatikainen et al., 2008), replacing two scheduled routine 
in-clinic visits by remote monitoring reduced the total expenditure of ICD follow-up by 524€ 
per patient during the 9-month study period. In addition, an average of 100€ per patient was 
saved, because all unscheduled data transmissions during the study period were solved 
remotely and the patient did not need to come to the hospital for reassurance. Thus, 
depending on the number of unscheduled visits, it was calculated that the annual saving of 
remote monitoring was 524-749€ per patient (Table 2). Further prospective health economic 
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studies are presently underway. They are aimed at assessing the economic impact of remote 
monitoring from the societal perspective and from the healthcare payer’s perspective. 
 
 In-clinic F-U Remote F-U Savings 
Number of scheduled visits   
In-office visits* 164 82  
Remote data transmission** 0 82  
Direct cost    
In-office visit (210 € per visit) 34440.00 € 17220.00 € 17220.00 € 
Remote monitoring (55 € per visit) 0.00 € 4510.00 € -4510.00 € 
Patient fee (22 € per in-office visit) 3608.00 € 1804.00 € 1804.00 € 
Indirect cost   
Traveling (77.68 € per in-office visit) 12195.04 € 6097.52 € 6097.52 € 
Accommodation (20.18 € / night)  40.36 € 20.18 € 20.18 € 
Sickness allowance (44 € / day) 1672.00 € 836.00 € 880.00 € 
Total costs 51955.40 € 30487.70 € 21467.70 € 
Total costs per patient 1267.20 € 743.60 € 523.60 € 
Table 2. Comparison between the cost of ICD follow-up according to the generally applied 
in-clinic follow-up scheme and remote monitoring. Adapted from Raatikainen et al. (2008). 
9. Summary and future directions 
In summary the major benefits of the currently available remote monitoring systems 
include: 
• Improved quality of patient care 
• Improved patient safety 
• More efficient device clinic workflow 
• Increased patient convenience  
• Potential cost savings 
The reality on the ground is that physicians should also have the ability to make 
adjustments to certain programmed ICD parameters remotely. As technology continues to 
evolve, a variety of new applications related to cardiac monitoring will emerge and an 
exponential growth in implementation of remote monitoring for the surveillance of a variety 
of devices including all new ICDs, pacemakers and other implantable disease monitors is 
likely to occur. Meanwhile, a wide range of medico-legal and reimbursement issues needs to 
be resolved before full implementation of the technology. 
10. Conclusions 
Remote monitoring has become the preferred method for ICD follow-up. It provides a 
tremendous convenience for the patients and reduces the burden of in-clinic follow-up on 
healthcare system. Continuous remote monitoring with fully automated wireless system 
also enables early detection of clinically relevant events and alerts physicians, allowing 
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earlier medical intervention that increases the level of patient care. Despite 24/7 
surveillance, the technology is not a substitute for an emergency system and should not 
create a false sense of complete security. 
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